You are Unregistered, please register to gain Full access.
Welcome to the xenoMED, an online Medical Community where Academically sound, Professionally conscious and Socially responsible Medical Students, Doctors & Health Professionals interact with each other globally.
Medicine is the only profession that incessantly tries to destroy its own existence. Howsoever you may be associated with basic and/or clinical medicine - student or professor, physician or surgeon, undergraduate or postgraduate - this is your place to share your knowledge, and learn more. Just get the message across!
You are currently viewing our communiy as a guest which gives you limited access to view most discussions and access our other features. By joining our free community you will have access to post topics, communicate privately with other members (PM), respond to polls, upload content and access many other special features. Registration is fast, simple and absolutely free so please, Join Our Medical Cummunity Today!
If you have any problems with the registration process or your account login, please contact us.
Phase I Data For Exelixis' Kit Inhibitor XL820 Presented At EORTC -
09-11-2006, 01:20 AM
Exelixis, Inc. (Nasdaq: EXEL) announces that preliminary Phase I results were reported today from an ongoing trial of XL820, an oral small molecule compound which inhibits KIT, PDGF and VEGF and is designed to inhibit tumor growth and angiogenesis. [click link for full article]
Angel xenoMED | NDR “Nothing brings me more happiness than helping people in the society. It is a goal and an essential part of my life - a kind of destiny.”
The Following User Says Thank You to Angel For This Useful Post:
Linear Mode
